News for Aroa Biosurgery Limited (ARX.AX)

Published at

Jan 29, 2025 6:44 AM

by themarketherald.com.au

mixed

mixed

ASX Market Close: Westpac & UBS predict February rate cut | January 29, 2025

The critical trimmed mean inflation measure was up 3.2% on an annual basis, compared to 3.6% in the September quarter.

PLS.AX DRO.AX WCN.AX AX1.AX ARX.AX BENPG.AX BENPF.AX BEN.AX

Read more →
Published at

Jan 17, 2025 3:08 AM

by prnewswire.com

positive

positive

New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.

/PRNewswire/ -- New Zealand headquartered soft tissue regeneration company Aroa Biosurgery recently announced the publication of further strong clinical...

ARX.AX

Read more →
Published at

Nov 26, 2024 4:01 PM

by gurufocus.com

positive

positive

Aroa Biosurgery Ltd (ASX:ARX) H1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

Total Revenue: $39 million for the first half of the year.Product Gross Margin: 87%.Normalized EBITDA Loss: $1.5 million.Cash Balance: $22 million at the end o

ARX.AX

Read more →
Published at

Oct 24, 2024 1:30 PM

by globenewswire.com

mixed

mixed

Soft Tissue Repair Market Size to Worth USD 12.78 Billion by 2034 With 5.6% CAGR | Fact.MR Report

Increasing Number of People Getting Affected with Diabetes-Related Gangrene Worldwide Pushing Demand for Soft Tissue Repair Products...

SNNUF SNN SN.L BDXB BDX.MX BDX ARX.AX 0R19.L SYK.MX SYK.DE SYK S1YK34.SA 0R2S.L MDTN.MX MDT.BA MDT BAX.MX BAX 2M6.DE 0Y6X.L 0QK8.L

Read more →
Published at

Mar 29, 2024 12:36 AM

by gurufocus.com

positive

positive

Full Year 2022 Aroa Biosurgery Ltd Earnings Call Transcript

May 24, 2022 / 01:30AM GMTSimon Hinsley - Aroa Biosurgery Limited - IR Good morning, and welcome to Aroa Biosurgery's full-year results webinar for the financia

ARX.AX

Read more →
Published at

Jan 30, 2024 7:22 AM

by themarketherald.com.au

positive

positive

TMH Market Close: ASX200 hits record high as IT stocks surge

The ASX200 closed up about 0.3 per cent, after earlier setting a new record at 7630 points.

MP1.AX CCX.AX ARX.AX AMH.AX ADD.AX

Read more →
Published at

Nov 13, 2023 10:30 AM

by globenewswire.com

mixed

mixed

Global Soft Tissue Repair Market to total US$ 10,814.7 Million by 2033, registering a CAGR of 4.5% | Future Market Insights, Inc.

The US leads North American soft tissue repair market growth, driven by healthcare sector expansion, renowned manufacturers, and high demand due to chronic...

ARX.AX JNJ DJNJ3.BA DJNJ2.BA BDXB BDX.MX BDX 0R19.L

Read more →
Published at

Oct 27, 2023 3:00 AM

by globenewswire.com

mixed

mixed

Biosurgery Market is Projected to Reach an Estimate of $27,324.80 Million by 2030, With CAGR of 9.1%: Allied Market Research

The global biosurgery market is experiencing growth due to various factors such as an increase in the prevalence of chronic disease, a surge in the number...

BDXB BDX.MX BDX BAX.MX BAX ARX.AX 0R19.L 0QK8.L MDTN.MX MDT.BA MDT 2M6.DE 0Y6X.L

Read more →
Published at

May 31, 2023 6:49 AM

by moneymorning.com.au

positive

positive

Aroa Biosurgery [ASX:ARX] Posts FY23 Results and Shares FY24 Outlook

Biotech Aroa has released its audited results for the 2023 financial year, hitting targets and achieving its expectations. The company looks ahead with a positive perspective on FY24, with the group providing new guidance today.

ARX.AX

Read more →
Published at

Apr 30, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

PSQ.AX PGC.AX OSX.AX OPT.AX OPT NOXOF NOX.AX IUGNF IMU.AX GSS.AX CYP.AX CKDXF BPH.AX ATX.AX 4DX.AX ZNO.AX SCU.AX RSH.AX PXSLY PXS.AX PAB.AX OCC.AX NC6.AX KZA.AX KMLXF IHL.AX IDT.AX FDMDF DVL.AX CMP.AX BITRF BIT.AX ARUXF AMT.AX ACR.AX 1AD.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX RNO.AX RHY.AX RHT.AX RGS.AX RAC.AX PYC.AX PNV.AX PCK.AX PBP.AX OVN.AX OSL.AX ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX ICR.AX HCT.AX GTG.AX GLH.AX EYE.AX DXB.AX CSL.AX CPH.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX AT1.AX ARX.AX AMDHF ALC.AX ADR.AX ADO.AX 1ST.AX

Read more →
Published at

Mar 13, 2023 2:15 PM

by globenewswire.com

mixed

mixed

Soft Tissue Repair Market to Surpass US$ 10,392.1 Million by 2030, Says Coherent Market Insights (CMI)

Revolutionizing Soft Tissue Repair: Innovations and Advancements in Regenerative Medicine and Tissue Engineering...

TINLY BAX.MX BAX 3401.T 0QK8.L CNMD BSX.MX BSX-PA BSX B1SX34.SA 0HOY.L ORTIF ORTH.CN MSON MDTN.MX MDT.BA MDT JNJ DJNJ3.BA DJNJ2.BA ARX.AX 2M6.DE 0Y6X.L

Read more →
Published at

Feb 1, 2023 5:46 PM

by stockhead.com.au

mixed

mixed

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

PYC.AX PSQ.AX PGC.AX MSB.AX KZA.AX EYE.AX DVL.AX CAN.AX BXN.AX BNOEF BNO.AX ADO.AX SOMNF SOM.AX RSH.AX RHT.AX RGS.AX OSX.AX OSL.AX ONE.AX OIL.AX NXSCF NXS.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IUGNF IMU.AX IDT.AX GLH.AX CYP.AX CMP.AX CAJ.AX AT1.AX ADR.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SCU.AX RNO.AX RHY.AX RAC.AX PXSLY PXS.AX PNV.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MDR.AX LBT.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GTG.AX GSS.AX FDMDF DXB.AX CPH.AX CKDXF CGS.AX CALZF BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX AMDHF ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 19, 2023 5:50 PM

by stockhead.com.au

mixed

mixed

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

ZNO.AX ZLD.AX RAP.AX PSQ.AX PIQ.AX PBP.AX PAA.AX MXC.AX IPDQF IPD.AX IDT.AX GLH.AX CGS.AX BXN.AX 1AD.AX SOMNF SOM.AX SHL.AX RSH.AX RGS.AX PGC.AX PCK.AX OVN.AX OSX.AX OSL.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDC.AX LBT.AX KZIA KZA.AX KMLXF IVX.AX IMMP IMM.AX IHL.AX GSS.AX FDMDF DVL.AX CYP.AX CPH.AX CAN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AT1.AX ARX.AX AKU.TO AKU ADR.AX 4DX.AX 1ST.AX VTG.AX VLS.AX UBI.AX SCU.AX RNO.AX RHY.AX RHT.AX RAC.AX PYC.AX PXSLY PXS.AX PNV.AX PAB.AX OPT.AX OPT ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF IUGNF IMU.AX IMRNW IMRN IMC.AX ICR.AX HCT.AX EYE.AX DXB.AX CMP.AX CKDXF CALZF CAJ.AX ATX.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jan 4, 2023 6:02 PM

by stockhead.com.au

mixed

mixed

Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

TD1.AX RSH.AX PCK.AX MX1.AX KMLXF DVL.AX CAJ.AX BNOEF BNO.AX ARX.AX ADR.AX 1ST.AX ZNO.AX RHY.AX RAC.AX PYC.AX PSQ.AX PGC.AX OVN.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MDC.AX KZA.AX IPDQF IPD.AX IDT.AX GTG.AX CYP.AX CPH.AX CAN.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PNV.AX PBP.AX PAB.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MVF.AX MEM.AX MDR.AX LBT.AX IVX.AX IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GSS.AX GLH.AX FDMDF EYE.AX DXB.AX CMP.AX CKDXF CGS.AX CALZF AT1.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Dec 22, 2022 3:01 PM

by stockhead.com.au

mixed

mixed

After a dismal year for ASX health stocks 2023 is showing signs of a recovery

The ASX health sector is down more than 8% as 2022 comes to end but in signs of optimism for 2023, Morgans has a basket of stocks to watch.

TD1.AX PME.AX NURPF NEU.AX NAN.AX MEM.AX KZIA KZA.AX HXL.AX HHI.AX EX1.AX SCU.AX PIQ.AX OSL.AX MVF.AX EBO.NZ EBO.AX CSLN.MX CSLLY CSL.AX CMXHF BXPHF BOT.AX AVR.AX AMEUF AJJ.AX ADO.AX ZLDAF ZLD.AX WFL.AX VIP.AX VHT.AX UBI.AX SIG.AX REG.AX PNV.AX PBP.AX OVN.AX NTI.AX MEB.AX MDBIF LCT.AX CSX.AX CRON CPH.AX COPHF CAU.AX CALZF AT1.AX ARX.AX ANR.AX

Read more →
Published at

Nov 30, 2022 8:10 PM

by stockhead.com.au

mixed

mixed

Check Up: The world's most expensive drug costs $3.5 MILLION a shot

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

PAB.AX OCC.AX NC6.AX MDR.AX IMM.AX GTG.AX GSS.AX EYE.AX CSLN.MX CSLLY CSL.AX CMXHF BPH.AX SHL.AX RAC.AX PSQ.AX ONE.AX NYR.AX NXSCF NXS.AX MXC.AX KZA.AX FDMDF DXB.AX DVL.AX CYP.AX CPH.AX CGS.AX AT1.AX ARX.AX ARUXF AMDHF ALC.AX ACR.AX 4DX.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX PYC.AX PXSLY PXS.AX PNV.AX PGC.AX PCK.AX PBP.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OIL.AX NOXOF NOX.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IVX.AX IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMC.AX IHL.AX IDT.AX ICR.AX HCT.AX GLH.AX CMP.AX CKDXF CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AMT.AX ADR.AX ADO.AX 1ST.AX 1AD.AX

Read more →
Published at

Nov 23, 2022 7:50 PM

by stockhead.com.au

mixed

mixed

How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

VTG.AX NEU.AX MXC.AX KZA.AX CSL.AX COH.AX BWXXF BWX.AX AT1.AX ADR.AX ADO.AX ZNO.AX ZLD.AX UBI.AX TD1.AX SHL.AX RSH.AX RHT.AX RAC.AX PNV.AX PBP.AX OVN.AX OSX.AX OSL.AX OCC.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX ICS.AX ICR.AX EYE.AX CPH.AX CMP.AX CALZF BXN.AX AMDHF 1ST.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OPT.AX OPT ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDR.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF DXB.AX DVL.AX CYP.AX CKDXF CGS.AX CAN.AX CAJ.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Nov 2, 2022 8:30 PM

by stockhead.com.au

mixed

mixed

Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.

ZNO.AX RHT.AX LBT.AX KZA.AX IUGNF IMU.AX ICR.AX EPN.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 1ST.AX ZLD.AX RAC.AX PNV.AX PBP.AX ONE.AX OIL.AX NXSCF NXS.AX MDR.AX IPDQF IPD.AX IMRNW IMRN IMC.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX CYP.AX CALZF BNOEF BNO.AX 4DX.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IMM.AX IHL.AX IDT.AX HCT.AX DXB.AX DVL.AX CPH.AX CMP.AX CKDXF CGS.AX CAN.AX CAJ.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX AT1.AX AMDHF ADR.AX ADO.AX 1AD.AX

Read more →
Published at

Oct 20, 2022 9:00 PM

by stockhead.com.au

mixed

mixed

Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

PXSLY PXS.AX PAB.AX OSL.AX MEM.AX ILA.AX GLH.AX CAJ.AX BPH.AX AMDHF AGN.AX ZLD.AX UBI.AX TD1.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PGC.AX PBP.AX OSX.AX OPT.AX OPT OIL.AX OCC.AX NXSCF NXS.AX NOXOF NOX.AX NC6.AX MXC.AX MEB.AX MDR.AX MDC.AX MDBIF KMLXF IPDQF IPD.AX IMRNW IMRN IMC.AX IHL.AX HXL.AX GTG.AX EYE.AX DVL.AX CPH.AX CKDXF BWXXF BWX.AX BITRF BIT.AX AT1.AX ARUXF ACR.AX 1ST.AX ZNO.AX VTG.AX VLS.AX SOMNF SOM.AX RHT.AX RAC.AX PSQ.AX PNV.AX PCK.AX OVN.AX ONE.AX NYR.AX MX1.AX MVF.AX LBT.AX KZA.AX IVX.AX IUGNF IMU.AX IMM.AX IDT.AX ICR.AX HCT.AX GSS.AX FDMDF DXB.AX CYP.AX CMP.AX CGS.AX CAN.AX CALZF BXN.AX BNOEF BNO.AX ATX.AX ARX.AX AMT.AX ALC.AX ADR.AX ADO.AX ACW.AX 4DX.AX 1AD.AX

Read more →
Published at

Oct 18, 2022 9:30 PM

by stockhead.com.au

mixed

mixed

Innovation never sleeps: Franklin Templeton says watch these 5 big tech shifts this quarter

Tech innovation has no time to wait for recessions to end. Franklin Equity Group has flagged five advancements for this quarter to check out.

OSX.AX NWS.AX ACB.AX VR1.AX FMG.AX AVH.AX ARX.AX AND.AX

Read more →